CD163 and intrahepatic cholangiocarcinoma: In both ICC and DCC, higher density of PD-L1+  M1 TAMs (CD45+CD3−CD20−CD56−CD66b−Tryptase−CSF1R+CD68+CD163−PD-L1+) or PD-L1+ M2 TAMs (CD45+CD3−CD20−CD56−CD66b−Tryptase−CSF1R+CD68+CD163+PD-L1+) is associated with poorer survival even though M1 TAMs in general are not associated with poor survival (Fig. 4G–I).